Trial Profile

A Phase II, Multi-center, Single Arm, Open Label Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 17 Jul 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Panobinostat (Primary) ; Bortezomib; Dexamethasone
Indications Multiple myeloma
Focus Therapeutic Use
Acronyms PANORAMA 2; PANORAMA-II
Sponsors Novartis; Novartis Pharmaceuticals

Most Recent Events

21 Jun 2020 Results presented at the 25th Congress of the European Haematology Association
06 Nov 2014 According to a Novartis media release, the FDA Oncologic Drugs Advisory Committee did not recommend panobinostat for previously treated multiple myeloma.
04 Nov 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com